Loading clinical trials...

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma | Clinical Trials | Clareo Health

RECRUITINGPHASE1

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Pilot/Phase I Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

NCT06014905•Javier Villaneuva-Meyer, MD

Summary

This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior

Detailed Description

Primary Objective: I. To assess the feasibility of hyperpolarized 13C MR imaging as a new and unique tool in the characterization of aggressive tumor behavior in participants with meningioma. Secondary Objectives: I. To define the most appropriate parameters for obtaining hyperpolarized 13C data from meningioma patients with a run-in study to optimize spatial and temporal resolution and coverage by detecting signal amplitudes and time dynamics. II. To measure tumor pyruvate-to-lactate, pyruvate-to-alanine, and pyruvate-to-bicarbonate conversion by 13C pyruvate MR imaging in participants with meningioma planning to undergo surgical resection within 4 weeks, using parameters. Outline: Participants will receive a single imaging procedure using HP 13C pyruvate. Participants will then be followed-up for 30 days after completion of the study or until voluntary withdrawal or death.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Known (histopathologically confirmed) or presumed meningioma based on imaging with measurable disease on MRI that shows gadolinium enhancement (at least one cm diameter) intracranially (e.g., not confined to skull base alone).
•a. Thirty of the participants plan to have surgical resection within 4 weeks
•2. Participants cannot have contraindication to MRI examinations.
•3. Age \>=18 years.
•4. Have a life expectancy of \>12 weeks.
•5. Karnofsky Performance Status \> 60%.
•6. Participants must have adequate renal function (creatinine \< 1.5 mg/dL) before imaging. This test must be performed within 60 days prior to hyperpolarized imaging scan.
•7. Participants must sign an informed consent indicating that they are aware of the investigational nature of this study.
•8. Participants must sign an authorization for the release of their protected health information.

Exclusion Criteria

•1. Has any significant medical illnesses that in the investigator's opinion cannot be adequately controlled with appropriate therapy, would compromise the patient's ability to participate in this study or any disease that will obscure toxicity or dangerously impact response to the imaging agent.
•2. Uncontrolled blood pressure (Systolic BP≥140 mmHg or diastolic BP ≥\>=90 mmHg) despite an optimized regimen of antihypertensive medication.
•3. Has a history of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission and off of all therapy for that disease for a minimum of 3 years.
•4. Participants must not be pregnant or breast feeding. Women of childbearing potential are required to obtain a negative pregnancy test within 14 days of Hyperpolarized Imaging scan. Effective contraception (men and women) must be used in participants of child-bearing potential.
•5. Participants must be excluded from participating in the study if they are not able to comply with the study and/or follow-up procedures.

Locations (1)

University of California, San Francisco

San Francisco, California, United States

Key Dates

Start Date

September 1, 2023

Primary Completion Date

September 30, 2026

Completion Date

September 30, 2026

Last Updated

May 25, 2025

Enrollment

ESTIMATED participants

Conditions

Meningioma

Interventions

Hyperpolarized carbon C 13 pyruvate

DRUG

Magnetic Resonance Image (MRI)

PROCEDURE

Saline

OTHER

Contacts

Wendy Ma

CONTACT

(415) 514-4418 Wendy.Ma@ucsf.edu

Abemaciclib in Newly Diagnosed Meningioma Patients

NCT05940493

Meningioma

View study

RECRUITINGPHASE2

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014

Intracranial MeningiomaRecurrent Meningioma+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 25, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma

Inclusion Criteria

Exclusion Criteria

Abemaciclib in Newly Diagnosed Meningioma Patients

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE

Evaluation of the CONVIVO System

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Meningiomas